Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCOGU--Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium.

Business Wire • 15 hours ago

Veracyte (VCYT) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Feb 23, 2026

Veracyte to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference – Orlando, FL Presentation on March 3rd at 8:05 a.m. Eastern Time Leerink Partners Global Health Conference – Miami, FL Fireside chat on March 9th at 10:40 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by vi.

Business Wire • Feb 19, 2026

Here's How Veracyte Stock Is Placed Ahead of Q4 Earnings

VCYT heads into Q4 earnings with rising estimates, strong Decipher and Afirma volumes, and revenues seen up nearly 17% year over year.

Zacks Investment Research • Feb 16, 2026

Veracyte (VCYT) Loses 20.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Veracyte (VCYT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research • Feb 5, 2026

Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's.

Business Wire • Feb 4, 2026

Here's Why Veracyte (VCYT) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Feb 4, 2026

Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now

Veracyte (VCYT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Investment Research • Jan 30, 2026

Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again

Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Jan 26, 2026

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jan 22, 2026